Tibsovo® (ivosidenib) – New indication
October 24, 2023 - Servier announced the FDA approval of Tibsovo (ivosidenib), for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes (MDS) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.
Top